The Brain Tumor Center at The Jewish Hospital – Mercy Health, with Partners OHC and Mayfield, is Fourth in U.S. To Earn Joint Commission’s Gold Seal for Brain Tumor Care
FOR IMMEDIATE RELEASE
August 14, 2019
OHC is pleased to share that the Brain Tumor Center at The Jewish Hospital – Mercy Health has earned The Joint Commission’s Gold Seal of Approval® and Certification for brain tumor care. It is the fourth center of its kind in the nation to earn this certification by demonstrating continuous compliance with The Joint Commission’s performance standards. The Gold Seal is a symbol of quality that reflects a health care organization’s commitment to providing safe and quality patient care.
The Brain Tumor Center is a partnership of OHC (Oncology Hematology Care), Mayfield Brain & Spine, and Mercy Health to provide the region with comprehensive, state-of-the-art care at the Brain Tumor Center.
The certification recognizes health care organizations that provide clinical programs across the continuum of care for brain tumors. The certification evaluates how organizations use clinical outcomes and performance measures to identify opportunities to improve care, as well as to educate and prepare patients and their caregivers for discharge.
The Brain Tumor Center underwent a rigorous onsite review in June. During the visit, a team of Joint Commission reviewers evaluated compliance with related certification standards, including clinical information management, delivering and facilitating clinical care, performance measurement, and program management. The Joint Commission develops its standards in consultation with health care experts and providers, measurement experts and patients. The reviewers also conducted onsite observations and interviews.
OHC, the region’s premier source of treatment for nearly every form of adult cancer and complex blood disorder, announced its partnership in the Brain Tumor Center with Mayfield Brain & Spine and Mercy Health in 2018.
The center includes the region’s only Gamma Knife® ICON™ radiosurgery program, co-directed by Peter Fried, MD, a radiation oncologist with OHC who earned his fellowship in head and neck cancer at New York University Medical Center, and Mayfield’s Ronald Warnick, MD, fellowship-trained in neuro-oncology at the University of California, San Francisco.
“OHC’s radiation oncologists have been using Gamma Knife to destroy the tumor cells while causing little or no radiation damage to the surrounding normal tissue. OHC has treated more than 1,150 patients using Gamma Knife, giving them new hope and a vastly improved quality of life. In some cases, patients experience improvement within minutes of the procedure,” said Dr. Fried. OHC’s team of radiation oncologists includes Dr. Fried, Elizabeth H. Levick, MD, Marc Mosbacher, MD, and David Pratt, MD.
Prasad Kudalkar, MD, an OHC medical oncologist and hematologist who specializes in neuro-oncology, said a unique benefit for patients of the partnership is that it gives patients access to the newest treatments through clinical trials. OHC offers the most cancer clinical trials in the Cincinnati area thanks to its team of more than 30 dedicated researchers who are engaged daily in a passionate search for innovative treatment options. That dedication is evidenced by OHC’s participation over the last several years in 80 percent of clinical trials in which cancer treatments were ultimately approved by the FDA.
Through its affiliation with The US Oncology Network, a national network of independent physicians, OHC’s researchers have access to more than 300 clinical trials, including the ground-breaking CAR T-cell immunotherapy, the most promising treatment since the introduction of chemotherapy.
“OHC’s clinical trials program is one of only six community oncology practices in the nation recognized by the Conquer Cancer Foundation of the American Society of Clinical Oncology,” Dr. Kudalkar said. “This means we are dedicated to conquering cancer worldwide by providing patients with access to treatments in the communities we serve.”
Mayfield’s experience in brain tumor care is extensive. Its surgeons have performed more than 6,000 open surgeries, 3,600 radiosurgeries, and 1,150 Gamma Knife Procedures.
Directing the Brain Tumor Center at The Jewish Hospital is Mayfield’s Vincent DiNapoli, MD, PhD, a neurosurgeon who earned his fellowship in skull base surgery and neuro-oncology at the MD Anderson Cancer Center. Mayfield’s Yair Gozal, MD, PhD, fellowship-trained in skull base surgery at the University of Utah, also treats patients with brain tumors at the center.
“The Brain Tumor Center’s 22 physicians specialize in neurosurgery, otolaryngology (ear, nose and throat), radiation oncology, medical oncology, neurology, neuropathology, neuroradiology and rehabilitation medicine. Our center also includes the only skull base brain tumor program featuring fellowship-trained neurosurgeons and ENT surgeons, a multidisciplinary Brain Tumor Board and a nationally recognized bone marrow transplant program,” said Pat Davis-Hagens, President of The Jewish Hospital. “I congratulate the entire team for the dedication to top quality patient care. It’s their work that makes this certification – only the fourth of its kind awarded by The Joint Commission – possible.”
For more information about the Brain Tumor Center, please call OHC at 1-888-649-4800.